Morphological and biochemical studies of human colony-forming units-erythroid (CFU-E) have been hindered by their extreme rarity. Since burst-forming units-erythroid (BFU-E) develop into CFU-E, we used normal human blood BFU-E to generate large numbers of highly purified CFU-E in vitro. Using density centrifugation, sheep erythrocyte rosetting, surface immunglobulin positive cell depletion, adherence to plastic, and negative pn with monoclonal antibodies, human blood BFU-E were purified from 0.017 to 0368%, a 22-fold purification with a 43% yield. The panned cells were cultured in methylcellulose with recombinant erythropoietin (rEp) and conditioned medium for 9 d. These cells were then collected and CFU-E were further purified using adherence and density centrifugation. This yielded almost 107 erythroid colony forming cells with a purity of 70±18%.
Introduction
The study of the development of normal human erythroid progenitor cells, as well as diseased human progenitor cells has been hindered by a lack of pure reagents. Pure erythropoietin (Ep)' 1 . Abbreviations used in this paper: AB-, antibody-negative cells; AD-, nonadherent cells; CFU-E, colony-forming units-erythroid; BFU-E, burst forming units-erythroid; CFU-GM, colony-forming units-granulocyte
The Journal of Clinical Investigation, Inc. Volume 80, August 1987, [357] [358] [359] [360] [361] [362] [363] [364] [365] [366] (1) and recombinant Ep (rEp) (2) can now be obtained, but sufficient numbers of pure target cells for the measurement of biochemical alterations, or the characterization of membrane receptors, are readily available only in the murine system (3). Human burst-forming units-erythroid (BFU-E) have been highly purified from fetal liver and bone marrow tissues, but only in small numbers (4, 5) . Because ofthe heterogeneity ofbone marrow tissue and the low concentration of human colony-forming units-erythroid (CFU-E) in the bone marrow (6) , attempts to purify these cells using physical and chemical parameters have had very limited success.
Since it has been shown that BFU-E develop into CFU-E (7, 8) , we hypothesized that it should be possible to obtain highly purified human CFU-E in large numbers by culturing BFU-E progenitor cells found in human peripheral blood. Using the methods of density centrifugation, sheep erythrocyte rosetting, adherence to plastic dishes, and immunoadsorption (panning), human BFU-E derived from peripheral blood were partially purified, and were then cultured in methylcellulose in the presence of rEp for 9 d. Erythroid bursts that proliferated in the methylcellulose culture medium were collected and further purified using adherence to plastic dishes to remove remaining monocytes and macrophages, while dead cells and debris were removed by density centrifugation. These methods provided uniformly developed CFU-E in sufficient numbers to measure Ep binding as previously reported for murine CFU-E (9) .
The successful analysis of the molecular events that control CFU-E development depends on the purity, uniformity of maturation and number of these target cells. We demonstrate the isolation of human CFU-E that sufficiently meet these parameters to allow characterization of their morphology and measurement of specific binding of Ep.
Methods
Blood samples. Peripheral blood was obtained from normal adult volunteers who had previously signed consent forms approved by the Van- derbilt Committee for the Protection ofHuman Subjects and the Veterans Administration Research and Development Committee. Approximately 400 ml was collected in sodium heparin (Upjohn Co., Kalamazoo, MI) at a final concentration of 20 U/ml.
Cell separation by density centriifugation. Light density mononuclear peripheral blood cells were separated over Ficoll-Hypaque (FH; 1.077 g/cm3; Pharmacia Fine Chemicals, Piscataway, NJ; Winthrop-Breton Laboratories, New York) at 400 gfor 25 min at 240C (10) . The interface mononuclear FH cells were collected, washed twice with alpha minimum essential medium (a-MEM) containing 2% heat-inactivated fetal calf serum (FCS; Hyclone Laboratories, Logan, UT) and were resuspended in 50% Iscove's modified Dulbecco's medium (IMDM/50% a-MEM; macrophage; Ep, erythropoietin; ERF-, nonerythrocyte rosette-forming cells; FH, Ficoll-Hypaque; GCT-CM, giant cell tumor-conditioned medium; HSA, human serum albumin; IMDM, Iscove's modified Dulbecco's medium; MC, methylcellulose; a-MEM, alpha minimum essential medium; SIg-, surface immunoglobin-negative cells.
both from Sigma Chemical Co., St. Louis, MO) at a concentration of 5 x 106 nucleated cells per ml.
Sheep erythrocyte rosette-forming cell depletion. Sheep red blood cells (Cappel Laboratories, Cochranville, PA) were washed three times with phosphate-buffered saline (PBS) and were resuspended in a-MEM at a concentration (vol/vol) of0.5% (1 1). The FH light density mononuclear blood cells and sheep erythrocytes were mixed in equal volumes, and were incubated for 5 min in a 370C water bath. After centrifugation at 130 g for 10 min at 240C, two-thirds of the supernatant was removed, and the cells were incubated in the presence of 50 Ml of heat-inactivated pooled human AB serum for 60 min at 4VC. The cell pellet was then gently dispersed, and the cell suspension was centrifuged over FH at 400 g for 15 min at 240C. The interface mononuclear cells (ERF-) were collected, washed twice, and resuspended in 50% IMDM/50% a-MEM containing 2% FCS.
Surface immunoglobulin-positive cell depletion. A modification of the method reported by Chess et al. (12) was used. The ERF-cells were incubated at 4VC for 80 min in 100 X 20 mm plastic tissue culture dishes (Becton Dickinson Co., Oxnard, CA) that had been previously coated with affinity-purified sheep anti-human IgG specific for the F(ab)2 fragment (Cappel Laboratories, Malvern, PA). The cell concentration was 5 X 106 nucleated cells/ml and 5 ml were applied to each plate. The nonadherent cells (SIg-) were removed with two gentle washes and the cells were centrifuged at 400 g for 10 min at 240C.
Adherent cell depletion. The ERP, SIg-mononuclear cells were resuspended in 50% IMDM/50% a-MEM with ribonucleosides and deoxyribonucleosides, containing 20% FCS and 10% GCT conditioned medium (GCT-CM) (Gibco Laboratories, Grand Island, NY). 10 ml of the cell suspension, at a concentration of 5 X 106 nucleated cells/ml, were incubated in 75 cm2 tissue culture polystyrene flasks (Becton Dickinson & Co.) overnight at 37°C in a 5% CO2 atmosphere (13) . The nonadherent day 1 cells (AD-) were removed with three gentle washes and were centrifuged. Antibodycoated cell depletion. The ERF-, SIg-, AD-day 1 mononuclear cells were cooled to 3°C and were suspended at 70 X 106 cells/ ml in 25 ,ul of CD1 lb/OKM*l (20 Mg/ml), 25 ul of CD2/OKT*1 1 (10 Mg/ml) (Ortho Diagnostic Systems Inc., Raritan, NJ), 50 Ml of CD45R/ My 11, and 50 Ml of My 23 to coat granulocytes (My 23k, OKM*1+), monocytes (My 23+, OKM*1+), colony-forming units granulocyte-macrophage (CFU-GM) (My 1 1+), T(OKT*l 1+) and B(My 1 1+) lymphocytes, and natural killer cells (OKM*1+, My 23+) (14) (15) (16) (17) . The latter two antibodies were used as spent hybridoma tissue culture supernatant. My 23 is an IgG, monoclonal antibody raised by immunization of a mouse with normal human granulocytes. It binds selectively to granulocytes, monocytes, and natural killer cells from peripheral blood, labeling these cells intensely, but does not bind to colony-forming units (Warren, J., L. C. Strauss, and C. I. Civin, unpublished data).
The cell suspension was gently rocked on a platform at 0°C for 60 min and the cells were then washed twice with a-MEM containing 2% FCS, and once with IMDM containing 2% FCS, before suspending them at 2 X 106/ml in IMDM containing 5% FCS (4, 5) . 5-ml aliquots were incubated at 4°C for 90 min in 100-mm plastic tissue culture dishes that had been previously coated with affinity-purified goat anti-murine IgG (Boehringer Mannheim Biochemicals, Indianapolis, IN). The antibodynegative (AB-) nonadherent cells were removed and centrifuged.
Preparation of immunoglobulin-coated plates. Panning was carried out by the method ofWysocki and Sato (18) . Plastic tissue culture dishes (100 X 20 mm) were incubated at room temperature with 10 ml of0.05 M Tris-HCI buffer, pH 9.5, containing 20 Mg/ml ofaffinity-purified goat anti-murine IgG or 25 ,ug/ml of affinity-purified sheep anti-human IgG. After 3 h, the plates were washed six times in PBS and once in PBS containing 1% FCS and were then stored at -20°C until they were used.
Culture procedure for BFU (6, 10) . BFU-E plated in plasma clots were fixed on day 15 and stained with benzidine-hematoxylin as described by McLeod et al. (19) . Enumeration of BFU-E was performed in accordance with the criteria of Clark and Housman (10).
Collection ofCFU-E from methykcellulose. On day 9 of incubation, 1 ml of a-MEM was dispersed into each well and gently mixed using a I-ml pipette. The mixture was collected in 50-ml conical tubes (Falcon Labware, Becton Dickinson and Co. Viable cell enrichment ofMC AD-cells. MC AD-cells were resuspended in 2 ml of IMDM containing 2% FCS and overlaid on the top of 2 ml of FH in a 12 X 75 mm polystyrene tube. After centrifugation at 600 g for 15 min at 24°C, the interface mononuclear cells (MC FH) were collected, washed three times, and resuspended in IMDM containing 2% FCS at 4°C. The viability ofthese cells was measured by dye exclusion using 0.2% trypan blue dye (21) .
Culture procedure for CFU-E. The MC FH cells were cultured at 37°C in a 0.5-ml plasma clot mixture containing 15% FCS, 15% pooled human AB serum, 1% HSA, penicillin/streptomycin, 1.3 mg/ml fibrinogen, 0.2 U/ml of thrombin and IMDM, with varying concentrations of rEp and varying cell concentrations. Clots were fixed and stained on day 15 ofincubation (15 d after obtaining blood) and CFU-E were defined as cells that gave rise to single colonies of 8-49 hemoglobinized cells (22, 23) while erythroid colony-forming cells were defined as cells that gave rise to colonies of two or more hemoglobinized cells.
Preparation of'25I-rEp. rEp was iodinated using IODO-GEN (Pierce Chemical Co., Rockford, IL by a modification ofthe method previously published [24, 25] rEp containing no more than 0.6 molecules of 1251 per molecule of rEp had > 95% retention of biological activity when assayed in vitro (25) .
Binding method. Microwell cluster plates (Costar, Cambridge, MA)
were preincubated in a 370C incubator with a humidified 5% CO2 at-mosphere, or at 00C. An aliquot (40 Ml) ofthe cell suspension was added to each well and the cells were preincubated for 15 min at 370C, or at 0C, and then 10 ,1 of '25I-rEp, containing 0.08-0.2 U was added. After the desired interval, 0.25 ml of PBS at 00C was added to each replicate and the cell suspensions were layered on 0.9 ml of 10% BSA in PBS, at 00C, in 1.5-ml microfuge tubes (9) . The cells were separated from the radioactive medium by centrifugation at 15,300 g for 4 min at 4VC. The tube contents were frozen using dry ice/ethanol, and the tips were then cut off above the pellet. The radioactivity of the pellet was measured in a well-type scintillation counter, using counting times sufficient to ensure precision within 3%. Nonspecific binding was measured by the same method, except that a 60-80-fold excess of unlabeled, partially purified (570 U/mg protein) or pure (70,000 U/mg protein) human urinary Ep, a gift ofDr. Eugene Goldwasser (1), was added with the 251-rEp. Specific binding is the difference between total and nonspecific binding. Murine epidermal growth factor was a gift of Dr. Stanley Cohen (26) . Human orosomucoid was a gift of Dr. Eugene Goldwasser (9) . Human transferrin and porcine sodium insulin were purchased from Calbiochem-Behring, La Jolla, CA. Recombinant human insulinlike growth factor I came from AMGen Biologicals and rat insulinlike growth factor II was purchased from Collaborative Research, Inc., Lexington, MA. All experiments were performed with two to four replicates as indicated and SD were calculated for all means with more than two replicates. Significance was calculated using the t test (27) . Electron microscopy. Cells in culture medium were mixed with an equal volume of 2% glutaraldehyde in phosphate buffer, pH 7.3, and centrifged to form a pellet. The pellet was resuspended in glutaraldehyde and incubated at 3°C for 2-3 h. After secondary fixation in 1% Millonig's phosphate-buffered osmium tetroxide, the cells were stained en bloc with 0.5% aqueous uranyl acetate. The cells were then dehydrated and embedded in Araldite. Thin sections were stained with uranyl acetate and lead citrate and examined in an electron microscope (EM 200, Philips Medical Systems, Inc., Shelton, CT).
Results
Purification of BFU-E from human peripheral blood. Table I shows the mean yield and enrichment of BFU-E observed in four experiments when FH separated mononuclear cells were sequentially purified by depletion of sheep erythrocyte rosetteforming cells, surface immunoglobulin-positive cells, adherent cells, and cells bearing surface markers for the monoclonal antibodies CD2/OKT* I 1, CD I lb/OKM* 1, CD45R/My 1 1, and My 23. To determine the number of BFU-E, each fraction was cultured in the plasma clot system. Through these sequential depletion procedures human blood BFU-E were purified from 0.017% (FH cells) to 0.368% (AB-cells), a 22-fold purification with a 43% yield. A high cell viability of88-98% was maintained throughout the 24-h period ofpurification. BFU-E were cultured under conditions that favored erythroid growth, and using ABcells, non-BFU-E colonies were greatly reduced compared with cultures of FH cells.
Purification oferythroid colony-forming cellsfrom day 9 cells generated in methylcellulose. Day 9 cells derived from methylcellulose cultures of ERF-, SIg-, AD-, and AB-cells were collected and further purified using adherence to plastic plates and density centrifugation (MC FH cells). To assay for erythroid colony-forming cells the MC FH cells were cultured in the plasma clot system in the presence of rEp at 1 U/ml for 6 d (until day 15) . The MC cultures, which favored erythroid growth, gave rise to 43% erythroid colony forming cells by day 9, and after adherence and density centrifugation in FH, this was increased to 70% with a 77% yield ( Table II) . The MC cells and MC ADcells contained both dead cells and cell debris, but these were greatly reduced in the MC FH cells. When FH mononuclear peripheral blood cells were cultured in MC without sequential depletion and were collected on day 9 for plating in plasma clots, there was a significant contamination with granulocytemacrophage colonies (Fig. 1 A) . However, the colonies derived from the culture ofsequentially purified cells were almost entirely erythroid (Fig. 1 B) .
Morphology of erythroid colony-forming cells. By light microscopy ( Fig. 1 C) , MC FH day 9 early erythroid cells were identified as extremely immature cells characterized by a fine nuclear chromatin, a well-defined large nucleolus, high nuclear/ cytoplasmic ratio, a perinuclear clear zone and basophilic cytoplasm with pseudopods. Although these cells varied in size and often had a vesicular, expanded cytoplasm that distorted the nucleus, they consistently retained these common features. Mature erythroid cells were identified by standard criteria (28) . Proerythroblasts were distinguished from early erythroid cells by a smaller, less well defined nucleolus, and increased coarseness of the nuclear chromatin.
On electron microscopy ( Fig. 2 A and B ) the cell population of day 9 MC FH cells was composed of two major cell types. The first cell type was a primitive blast with a high nuclear/ cytoplasmic ratio, dispersed nuclear chromatin, and a prominent nucleolus (Fig. 2 A) . The cytoplasm contained clumps of mitochondria and the cell surface showed frequent pinocytotic ves- Sequentially purified BFU-E were cultured for 9 d in methylcellulose (MC) and were then sequentially fractionated by adherence to plastic (AD-) and FH density centrifugation. Each fraction was cultured in triplicate in the plasma clot system with 1 U/ml rEp, until day 15. Erythroid colonies of 2-64 cells were counted and mean values for six experiments ±SD are shown.
icles (Fig. 2 A, inset) . Granules were absent. The second major cell type consisted of more differentiated erythroid cells which varied from proerythroblasts to polychromatophilic erythroblasts. These cells showed smaller, more rounded nuclei with marginated chromatin and more abundant cytoplasm (Fig. 2  B (Table III) , a concomitant decline of early erythroid cells (Table III) , the percentage of erythroid colonyforming cells (Table IV) , and the size of the erythroid colonies (Table IV) were evident. Further culture of days 11-13 cells for a total of5 d showed that the small colonies generated by mature erythroblasts did not have any further increase in cell number indicating that the length ofcell culture was not limiting the size of these particular colonies.
A clear parallel relation was present between the number of early erythroid cells, the number and size of erythroid colonies, and also the number of CFU-E, by the classical definition of erythroid colonies consisting of 8-49 erythroblasts (22, 23). Since 56-59% of the days 8-9 MC FH cells were CFU-E, these cells are identified by light and electron microscopy as the early erythroid cells of Table III . It is also evident that mature erythroblasts only gave rise to colonies with less than five cells, and that early erythroid cells gave rise to a fraction of erythroid colonies that were smaller than classical CFU-E colonies.
Growth characteristics oferythroid colonyforming cells. The relation between the number oferythroid colonies and the number of day 9 MC FH cells plated in plasma clots in a concentration range of 125 to 2,000 cells/ml was a straight line through the origin (Fig. 3 A) . An increase in the number of erythroid colonies was present after the addition of 10 mU/ml of rEp and a plateau was found at 1 U/ml (Fig. 3 B) . The plateau occurred when 75% ofthe cells plated had given rise to erythroid colonies, and most likely represents the full erythroid growth capacity that was present rather than any accumulated toxicity of the rEp preparation. No erythroid colonies were present without the addition of rEp.
Specific binding of'25I-rEp to days [8] [9] [10] [11] [12] [13] (28) . Cells cultured for 8-9 d had more than 60% early erythroid cells while more extensive culture led to a predominance of mature erythroblasts.
row, blood, and fetal liver, only 0.1-1.0% of the cells are early erythroid progenitor cells (4-6, 10, 30). Identification and accurate characterization of the human Ep receptor have lagged mainly because of a lack of sufficient purity and quantity of these cells. Methods used in the purification ofnormal progenitor cells have included density gradient centrifugation (10), immune rosetting (31), fluorescence-activated cell sorting (32), negative or positive selection by panning (4, 5, 33) , and various combinations ofthese physical and immunologic techniques (4, 5, 34) . While these techniques have led to a significant progenitor enrichment, cell yields have been notably low (5, 6), particularly for the study of Ep binding to BFU-E or CFU-E. In mice, CFU-E have been purified in large numbers, but this has required either the administration ofthiamphenicol and phenylhydrazine (29) , which greatly elevates Ep levels, or the infusion ofa Friend virus strain that leads to a huge accumulation of CFU-E in the spleen (3). In human beings erythroid bursts have been plucked after 7 d of incubation in methylcellulose with Ep and have provided up to 5 X I05 of these cells (8) , but larger numbers of purified human CFU-E have not been available. Based on the use of murine spleen cells infected by the anemia strain of the Friend virus (9), we estimated that the number of erythroid progenitor cells that are necessary for an Ep binding study would be -107 and that the purification of CFU-E from normal human bone marrow would need > 2 X I09 bone marrow nucleated cells as starting cells assuming that the recovery was 100%. Under these circumstances it would be difficult to find sufficient normal donors to develop purification procedures and to conduct a suitable study.
For these reasons we began with the blood as a starting tissue. It was more readily available, and although CFU-E are not present in normal human blood, they can be derived from BFU-E (7, 8) . Indeed, the lack of erythroid progenitor cells other than BFU-E, in the blood, favored the purification of CFU-E in a relatively uniform state of development. The relatively common procedures of FH centrifugation and sheep erythrocyte rosetteforming cell depletion removed large numbers of contaminant red cells, platelets, granulocytes, and T lymphocytes with little loss of BFU-E. Surface immunoglobulin-positive cell depletion removed B cells and other cells containing Fc receptors while enriching the BFU-E by 1.5-fold. Overnight adherence lost little useable laboratory time or BFU-E, and removed mainly monocytes (13) to enhance the purification by another 1.5-fold. Additional contaminant cells were removed by the relatively simple method of negative panning that depended on the antibodies that were utilized. Many murine monoclonal antibodies (CDl lb/ OKM*1, CD3/OKT*3, CD8/OKT*8, CD2/OKT*l 1 [Ortho], CD5/Leu 1, CD2/Leu 5B, CD7/Leu 9, CDl9/Leu 12, Leu 19 [Becton Dickinson and Co.], CD45R/My 11 (17) , CDl 5/My 18 [33] , and My 23) to surface hematopoietic cell antigens were tried, at a variety of concentrations and volumes, and four were chosen as most useful: CDl lb/OKM*l, which is directed to an antigen on monocytes, granulocytes, and natural killer cells (14, 15) ; CD2/OKT*11, which is directed to the sheep erythrocyte receptor on T cells (16); CD45R/My 11, which removed CFU-GM and many B lymphocytes that expressed the My 11 antigen (17); and My 23, which removed mature granulocytes and monocytes. Purification of the blood BFU-E not only removed other progenitor cells whose colonies would dilute the CFU-E, but also reduced the total number of nucleated cells that had to be cultured for 8-10 days, and thereby reduced the magnitude and expense of the procedure.
Enhancement of CFU-E purity to 56-59% was not only dependent on these purification procedures, but also on 8-9 d of culture with rEp, which progressively expanded and enhanced the erythroid cell compartment. Optimum concentrations of GCT and rEp were added based on dose-response curves and with this medium a small percentage ofthe large erythroid bursts that grew in methylcellulose were mixed with granulocytes and megakaryocytes. These were not counted separately since our aim was to derive CFU-E irrespective of the source. Initially all of the preceding antibodies also were used for negative panning on day 9, but provided little increase in CFU-E purity. Adherence to Sephadex G-10 also was of little benefit. For this reason only adherence to plastic plates and FH density centrifugation were used after MC culture and these methods removed monocytes, macrophages, late erythroblasts, dead cells, and cell debris. 8  27  13  46  13  1  70  9  30  14  53  3  0  85  10  52  24  23  1  0  49  1 1  90  5  5  0  0  29  12  94  6  0  0  0  13  13  98  2  0  0  0  2 Replicate cells from the experiment in Table III were cultured in plasma clots in the presence of I U/ml of rEp until day 15. Clots were fixed, stained by benzidine, and the number of hemoglobin-containing cells per colony were counted. Cells harvested after 8-9 d of culture gave rise to 56-59% CFU-E (erythroid colonies of 8-49 cells), while cells cultured for a more extensive period gave rise to smaller erythroid colonies.
bers have not provided an independent measure of the number of these cells beyond a count of their descendent colonies, our method does provide such a measure. First, the cells that are plated are almost entirely single under the inverted microscope, and the cell concentration curve, with the plating of as few as 60-1,000 cells/well, is a straight line through the origin indicating that each colony arose from a single cell. Secondly, in some experiments < 7% of the cells, by light or electron microscopy had an appearance of nonerythroid, nonhomogeneous cells, and the total cell population provided 85% erythroid colonies. Thirdly, GM-CSF addition to replicate cells, without Ep, produced only an occasional very small granulocyte-macrophagecolony (< 0.5%), and no megakaryocyte colonies were evident under conditions that favored their development (Dessypris, E. N., K. Sawada, and S. B. Krantz, unpublished data). Finally, days 8-9 erythroid colony-forming cells consisted of 56-59% CFU-E and had 62-88% pure early erythroid cells by light microscopy, with both numbers declining in parallel. The difference in these figures represent mostly the formation of smaller erythroid colonies, but the definition ofa CFU-E as a cell that gives rise to erythroid colonies of 8-49 cells is arbitrary. It is not unreasonable to think that some CFU-E have a probability of less replication and will behave like more mature erythroid cells even though they are at a similar stage of development as other "traditional" CFU-E. Nevertheless, to accommodate this traditional definition we have defined our days 8-13 cells as erythroid colony-forming cells with CFU-E as a subset. Alternatively, it is possible that some of the early erythroid cells were further developed chemically than was apparent by light microscopy. These studies not only provide an independent measure of CFU-E by direct microscopy and enumeration, but they also provide sufficient numbers ofthese cells to demonstrate specific Ep binding sites. The '25I-rEp that was used retained more than 95% of its biologic activity (25) , and specificity of binding was shown by the uniqueness ofcompetition for binding by pure Ep and the direct relation of the amount of specific binding to the number of erythroid colony-forming cells. It appears that little Ep specific binding to late erythroblasts occurs, which is compatible with experiments using murine cells (35) . This is the first demonstration ofspecific Ep binding to human CFU-E, but further studies are necessary to characterize the number, dissociation constant(s) and molecular size of these putative human Ep receptors. We believe that these studies have important implications for the study of normal erythropoiesis in human beings and the study ofa wide variety ofanemias and polycythemias. First, this work should enhance the investigation of normal erythroid development by permitting the study of the sequence of chemical events during normal human terminal erythroid differentiation using peripheral blood, a readily available source ofcells. Second, the normal sequence can be compared to the sequence of developmental events in individuals with a diverse number ofanemias and polycythemias as long as they have erythroid progen- When the specific binding of '25I-rEp (i) was measured during this time it was also greatest on days 8-9 and declined in parallel with the 
